万春医药上涨6.25%，报1.87美元/股，总市值7542.14万美元

Group 1 - The core viewpoint of the article highlights the financial performance and market position of BeyondSpring Inc. (BYSI), a biopharmaceutical company focused on innovative cancer therapies [1] - As of August 25, BYSI's stock opened at $1.87 per share, reflecting a 6.25% increase, with a total market capitalization of $75.42 million [1] - Financial data shows that for the period ending June 30, 2024, BYSI reported total revenue of $1.00 million, representing a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, indicating a 42.91% increase in losses compared to the previous year [1] Group 2 - BeyondSpring is a clinical-stage biopharmaceutical company established in 2013, headquartered in the United States, focusing on the development of novel cancer therapies, including advanced tumor immunotherapy [1] - The company's primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - The target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [1]